» Articles » PMID: 21886430

Co-occurring Amphetamine Use and Associated Medical and Psychiatric Comorbidity Among Opioid-dependent Adults: Results from the Clinical Trials Network

Overview
Publisher Dove Medical Press
Specialty Psychiatry
Date 2011 Sep 3
PMID 21886430
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND: In response to the rising rate of treatment admissions related to illicit use of amphetamines (eg, methamphetamine), we examined the prevalence of amphetamine use among treatment-seeking, opioid-dependent adults, explored whether amphetamine users were as likely as nonamphetamine users to enroll in opioid-dependence treatment trials, and determined whether amphetamine users manifested greater levels of medical and psychiatric comorbidity than nonusers. METHODS: The sample included 1257 opioid-dependent adults screened for participation in three-multisite studies of the National Drug Abuse Treatment Clinical Trials Network (CTN001-003), which studied the effectiveness of buprenorphine for opioid detoxification under varying treatment conditions. Patients were recruited from 23 addiction treatment programs across the US. Medical and psychiatric comorbidity were examined by past-month amphetamine use (current vs former) and route of administration. Five mutually exclusive groups were examined, ie, nonusers, current amphetamine injectors, current amphetamine noninjectors, former amphetamine injectors, and former amphetamine noninjectors. RESULTS: Of the sample (n = 1257), 22.3% had a history of regular amphetamine use. Of the 280 amphetamine users, 30.3% reported injection as their primary route. Amphetamine users were more likely than nonusers to be white and use more substances. Amphetamine users were as likely as non-users to enroll in treatment trials. Bivariate analyses indicated elevated rates of psychiatric problems (depression, anxiety, hallucinations, cognitive impairment, violence, suicidal thoughts/attempts) and medical illnesses (dermatological, hepatic, cardiovascular, respiratory, neurological, seizure, allergy conditions) among amphetamine users. After adjusting for demographic variables and lifetime use of other substances: current amphetamine users and former injectors showed an increased likelihood of having medical illnesses and hospitalizations; current injectors had elevated odds of suicidal thoughts or attempts; current noninjectors exhibited elevated odds of anxiety, cognitive impairment, and violent behaviors; and former noninjectors had increased odds of depression. CONCLUSION: Treatment-seeking, amphetamine-using, opioid-dependent adults manifest greater levels of medical and psychiatric morbidity than treatment-seeking, opioid-dependent adults who have not used amphetamines, indicating a greater need for intensive clinical management.

Citing Articles

The association between opioids, environmental, demographic, and socioeconomic indicators and COVID-19 mortality rates in the United States: an ecological study at the county level.

Qeadan F, Mensah N, Tingey B, Bern R, Rees T, Madden E Arch Public Health. 2021; 79(1):101.

PMID: 34130741 PMC: 8204068. DOI: 10.1186/s13690-021-00626-z.


The Evolving Overdose Epidemic: Synthetic Opioids and Rising Stimulant-Related Harms.

Jones C, Bekheet F, Park J, Alexander G Epidemiol Rev. 2021; 42(1):154-166.

PMID: 33511987 PMC: 9200066. DOI: 10.1093/epirev/mxaa011.


Use of Amphetamine-Type Stimulants Among Emergency Department Patients With Untreated Opioid Use Disorder.

Chawarski M, Hawk K, Edelman E, OConnor P, Owens P, Martel S Ann Emerg Med. 2020; 76(6):782-787.

PMID: 32782084 PMC: 8048036. DOI: 10.1016/j.annemergmed.2020.06.046.


Responding to global stimulant use: challenges and opportunities.

Farrell M, Martin N, Stockings E, Borquez A, Cepeda J, Degenhardt L Lancet. 2019; 394(10209):1652-1667.

PMID: 31668409 PMC: 6924572. DOI: 10.1016/S0140-6736(19)32230-5.


Increases in methamphetamine use among heroin treatment admissions in the United States, 2008-17.

Jones C, Underwood N, Compton W Addiction. 2019; 115(2):347-353.

PMID: 31503384 PMC: 6982538. DOI: 10.1111/add.14812.


References
1.
Wu L, Woody G, Yang C, Blazer D . How do prescription opioid users differ from users of heroin or other drugs in psychopathology: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Addict Med. 2011; 5(1):28-35. PMC: 3082206. DOI: 10.1097/ADM.0b013e3181e0364e. View

2.
Darke S, Torok M, Kaye S, Duflou J . Cardiovascular disease risk factors and symptoms among regular psychostimulant users. Drug Alcohol Rev. 2010; 29(4):371-7. DOI: 10.1111/j.1465-3362.2009.00158.x. View

3.
McKetin R, McLaren J, Lubman D, Hides L . The prevalence of psychotic symptoms among methamphetamine users. Addiction. 2006; 101(10):1473-8. DOI: 10.1111/j.1360-0443.2006.01496.x. View

4.
Hendrickson R, Cloutier R, McConnell K . Methamphetamine-related emergency department utilization and cost. Acad Emerg Med. 2008; 15(1):23-31. DOI: 10.1111/j.1553-2712.2007.00006.x. View

5.
Corsi K, Booth R . HIV sex risk behaviors among heterosexual methamphetamine users: literature review from 2000 to present. Curr Drug Abuse Rev. 2009; 1(3):292-6. DOI: 10.2174/1874473710801030292. View